Orca will receive an upfront payment and further fees from
AstraZeneca with a potential total value of $122.5 million, the
companies said on Wednesday. Final payments will depend on the
success of Orca's so-called retinoic acid–related orphan nuclear
receptor gamma inhibitors.
(Reporting by Ben Hirschler; editing by David Clarke)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |